|
|
|
| Webinar: Connecting the World of Oligonucleotide R&D With Early Clinical Scale Manufacturing | Moving oligonucleotide production from R&D to early clinical manufacturing brings new challenges in quality, scalability, process development, and equipment. This webinar explores a requirements-driven approach to oligonucleotide manufacturing, from solid-phase synthesis through scale-up, and highlights advances in synthesizer technology. Gain practical insights into building robust, reproducible processes that support pharmaceutical development and manufacturing at clinical scale. Click here to learn more. |
|
|
|
|
In the opening clip from this Advancing RNA Live event, AbbVie’s Elaine Peters, Sanofi’s Philippe Talaga, and Tessera’s Ilya Shestopalov share the novel methods they’ve been watching the most closely in the mRNA-LNP development space, as well as the role these methods will play in elucidating more about our drug products’ quality attributes. |
|
|
|
By Mahmoud Khatib Al-Ruweidi | Drug discovery has usually treated transfer RNA as cellular infrastructure: indispensable, highly conserved, and therefore dangerous to perturb. That description is accurate but incomplete. | |
|
|
|
By Ranjan Batra, Ph.D., Chief Scientific Officer, and Doug Kerr, MD, Ph.D., Chief Medical Officer, Dyne Therapeutics | Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever. | |
|
|
|
A conversation with Samir Ounzain, Ph.D., CEO & Scientific Cofounder, HAYA Therapeutics | Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more. | |
|
|
|
|
|
| Leveraging The Benefits Of Isolator Technology In Fill-Finish | Article | By Sabrina Zirkle, Jubilant HollisterStier | Isolator technology enhances sterility assurance, reduces contamination risk, improves operator safety, and supports regulatory compliance, making it essential for modern aseptic fill-finish operations. |
|
|
|
|
|
| Assessing Early Human Immune Response Drivers | Webinar | Lonza | Review strategies to assess the potential for human immune response following the administration of an mRNA therapeutic, the associated LNP, and the protein encoded for by the mRNA. |
|
|
|
|
|
|
|
.png){kind=logo}
